{"id":"W2103845135","doi":"10.1200/jco.2012.30.15_suppl.8502","title":"Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with <i>BRAF<sup>V600E</sup></i>-mutated melanoma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":140,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Vemurafenib; Dacarbazine; Hazard ratio; Internal medicine; Interim analysis; Temozolomide; Metastatic melanoma; Gastroenterology; Oncology; Surgery; Randomized controlled trial; Confidence interval; Chemotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009375856,0.0008389901,0.001316757,0.0007374107,0.0002996238,0.00122877,0.001061678,0.0007597831,0.002484184],"category_scores_gemma":[0.006766465,0.0004815021,0.002546395,0.0008143763,0.0002777311,0.0008749365,0.0007625831,0.002263534,0.0005544223],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008625141,"about_ca_system_score_gemma":0.0009475075,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001019635,"about_ca_topic_score_gemma":0.002723147,"domain_scores_codex":[0.997723,0.001338104,0.0001358147,0.0002400307,0.0003947056,0.000168172],"domain_scores_gemma":[0.9948654,0.001514386,0.002039073,0.0004931428,0.0004093978,0.0006786737],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6484267,0.00476447,0.1280175,0.002924355,0.02366746,0.0005264032,0.000446128,0.0108905,0.02743824,0.0007609897,0.04048409,0.1116532],"study_design_scores_gemma":[0.1796577,0.09965728,0.6247171,0.0003870027,0.03665255,0.001283519,0.0001250082,0.005869832,0.01488769,0.0007683831,0.03577271,0.0002210513],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.916797,0.01218891,0.004437633,0.001196336,0.0003298716,0.001980836,0.05475004,0.0005190863,0.007800257],"genre_scores_gemma":[0.8974792,0.001766016,0.004544747,0.001634532,0.0002523984,0.001867469,0.08929095,0.0001553767,0.003009269],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009375856,"threshold_uncertainty_score":0.04958487,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07959961057608907,"score_gpt":0.3936601599823536,"score_spread":0.3140605494062645,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}